Back in the earlier decades of steroid chemistry, innovations like 21-Hydroxypregna-1,4,9(11),16-Tetraene-3,20-Dione-21-Acetate expanded the scope of synthetic corticosteroids. Researchers faced countless setbacks with purity, yields, and safety, but persistent efforts brought about a diverse family of glucocorticoid and mineralocorticoid analogs. The acetate esterification process proved a valuable functional tweak, boosting bioavailability and shelf life. Experience shows that every refinement in synthesis has come from those countless lab hours—mixing solutions, running columns, watching for subtle color shifts under glass. Each discovery built upon the work before it, whether improving selectivity, reducing side effects, or just making manufacture more reliable.
This compound belongs in the corticosteroid realm, acting on pathways crucial for regulating inflammation and multiple physiological responses. Its structure—a pregnane skeleton with double bonds and specific hydroxyl and ketone groups—gives it unique biological properties. The acetate form tackles two problems: it resists rapid breakdown and improves tissue uptake. In the clinic, such molecules sometimes fill gaps where natural corticosteroids fall short, addressing rare adrenal disorders or finding use in cutting-edge immunomodulatory therapies. These uses often depend on small structural tweaks matched to complex human biology, reminding us that chemists rarely work in isolation; the clinic always calls back to the bench.
Anyone who’s handled steroids in a lab will recognize the look and feel—crystalline, off-white, often slightly greasy. The melting point stands as a tell-tale sign of purity. Solubility tends to lean toward organic solvents like chloroform, ethanol, or acetone, but water does little work here. Careful manipulation of temperature, pressure, and solvent pH keep crystalline formation smooth; a rushed approach often clogs up separation equipment with stubborn, resinous lumps. Watch for sensitivity to air and light as well, as the more conjugated double bonds a molecule carries, the faster it degrades, which can drastically affect yield.
Every lab learns the importance of tight technical standards: purity minimums above 98%, limited residual solvents, specific optical rotation, and strict adherence to USP, Ph. Eur., or JP monograph requirements. Labels need precise molecular weight, structural diagrams, and batch numbers. Regulatory needs change quickly, especially in pharmaceuticals, and falling behind means lost credibility, confiscated stock, or even litigation. In my experience, a well-managed label goes beyond traffic—clear safety symbols, expiration dates, storage instructions, and hazard classifications keep everyone in the chain safe, from delivery driver to bench researcher.
No shortcut works for the synthesis of this acetate; lab-scale or industrial, every step counts. The starting point usually sits in the steroid family—pregnenolone or hydrocortisone—undergoing catalytic oxidation, selective hydrogenation, and careful protection/deprotection cycles. Acetylation follows, with acetic anhydride often favored for cleaner reactions and easier purification. Even the smallest slip-up—using water-contaminated solvents, for example—means extra hours or lost batches. I’ve seen chromatography columns run for days chasing after a stubborn impurity only to discover moisture contamination set the column’s selectivity off. Rigorous analytical controls (NMR, HPLC, MS) monitor every batch to reveal deviations before they cause problems.
The molecule’s functional handle at C-21 gives chemists room for creativity. Acetate hydrolysis quickly regenerates the free hydroxyl, opening the door for other esterification strategies aimed at slow-release or targeted delivery. Reductive and oxidative changes at the other corners of the molecule fine-tune hormone receptor affinity or metabolic stability. Each derivatization step brings a risk of unwanted epimerization or cleavage, so real-time chromatography and spectroscopy matter for success. Synthetic modifications don’t just boost treatment outcomes—sometimes they help circumvent regulatory bottlenecks or patent barriers as well.
Chemists speak in shorthand; in documentation, 21-hydroxypregna-1,4,9(11),16-tetraene-3,20-dione-21-acetate sometimes appears as 21-Acetoxysteroid, 21-Acetoxy-Tetraenone, or 21-Acetoxypregnadienedione. Trade names change with region or supplier, and even a quick glance through catalogs reminds me to check for connections between synonyms—small distinctions can mean big differences in clinical or research effects.
Steroids like this compound can pose inhalation and dermal absorption risks, even at low airborne concentrations. I’ve watched experienced scientists slip into complacency, forgetting that chronic exposure piles up over years. Gloves, goggles, fume hoods, and prompt spill management remain non-negotiable. Good labs enforce regular air quality monitoring and waste disposal protocols backed by MSDS compliance and OSHA or local regulations. Safety audits and training sessions, though often seen as a chore, keep workplace accidents low—not just for the technicians but also administrative and custodial staff who may encounter traces outside the main laboratory area.
This compound and its analogs fit naturally into endocrine research, drug screening, and pharmaceutical formulation. Some years, new application patents emerge for rare immune diseases, topical anti-inflammatory gels, or even diagnostic reagents. Academic researchers use these molecules as tools to dissect hormonal feedback pathways with precision. The acetate version extends in vivo half-life, providing controlled exposure in animal models without constant redosing. Companies often invest heavily in formulation science, trying to wrangle every last bit of bioactivity while keeping side effects low. Constant cross-talk with clinicians helps adapt new application areas according to unmet medical needs.
Innovation rarely comes from isolation; teams blend skills from synthetic chemistry, analytical science, pharmacology, and even AI-guided modeling to drive new ideas. Once a new analog comes off the bench, rigorous preclinical testing begins—metabolic stability, receptor profiling, toxicity screens, and sometimes full pharmacokinetic studies across species. The push for greener chemistry affects every phase—solvent selection, energy use, and waste minimization all spark debate. Funding agencies and industrial partners alike look for sustainable, reproducible methods before greenlighting major scale-ups. Global regulatory frameworks shift frequently, and navigating multi-region approvals takes entire departments in larger firms.
No matter how many years chemists dedicate to refining a molecule’s profile, safety data guides every project. Chronic exposure studies in cells, animals, and sometimes human volunteers flag immediate and slow-developing risks. Steroidal compounds walk a thin line—inflammation suppression often brings metabolic or bone side effects. Reproductive toxicity still stands as a challenge in many cases. Experience shows that even a single flagged dataset can stop a molecule’s market journey unless researchers uncover ways to mitigate or sidestep the risk with modified compounds or redesigned delivery routes. Long-term registry studies in post-market phases ensure rare adverse events don’t slip through the cracks.
Few molecules attract as much ongoing interest as synthetic corticosteroid derivatives. Research continues to push for molecules with sharper selectivity and fewer off-target effects, looking toward next-generation immunosuppressants, targeted inhaled therapies, or depot formulations. Advances in delivery—nanoemulsions, lipid carriers, site-specific injectables—reshape what’s possible in chronic disease management. Public demand for evidence-based, safe, and cost-effective therapies grows louder with each passing year. Researchers and developers face the ongoing challenge: meeting medical needs without creating fresh problems, whether in terms of environmental impact, pharmacological dependence, or unforeseen health risks. Each discovery both answers and deepens old questions, keeping the scientific community’s curiosity alive.
21-Hydroxypregna-1,4,9(11),16-tetraene-3,20-dione-21-acetate sounds like a real tongue-twister, but its story isn’t as complicated as the chemistry behind it. In the world of medicine, people often run into these long steroid names, especially when dealing with issues linked to inflammation and hormone imbalance. This particular compound belongs to the corticosteroid family, known for their power to reduce swelling and help the body control countless processes. In real-world clinics, these medicines often step in for things like allergies, asthma, or auto-immune flare-ups: problems that refuse to take a day off.
Doctors reached for synthetic corticosteroids decades ago because they saw kids and adults dealing with debilitating symptoms, ranging from persistent skin irritations to stubborn lung inflammation. More refined steroids let them target these problems with fewer side effects. Researchers developed molecules like 21-Hydroxypregna-1,4,9(11),16-tetraene-3,20-dione-21-acetate specifically to fine-tune the action on inflamed tissue. People get shots, topical ointments, or even inhalers because doctors have learned that steroids can hush down an out-of-control immune system quickly, restoring some normalcy to lives disrupted by relentless symptoms.
Here’s the thing about a mouthful like 21-Hydroxypregna-1,4,9(11),16-tetraene-3,20-dione-21-acetate: it’s not just for show. Adding that acetate group changes how the drug is absorbed and processed in the body. Medicines get designed this way so the active parts release slowly, last longer, or cause fewer unwanted surprises. Through these tweaks, doctors can give lower doses and help people avoid the classic steroid pitfalls—brittle bones, weight gain, or spikes in blood sugar. The molecule’s root chemistry connects tightly to derivatives like triamcinolone acetonide, a common ingredient in creams and nasal sprays that families recognize in their medicine cabinets.
Steroids work well, but they’re known for side effects. Anyone who’s ever had to use a steroid for weeks knows stories about mood swings, bloating, or sleep that goes sideways. Some folks, myself included, have tried topical steroids for skin issues and watched their skin thin or develop odd discoloration after extra days of use. Doctors warn people not to get too comfortable with steroids, even when they clear up nagging symptoms. Regular monitoring and clear, plain-talk explanations from health providers go a long way. Seeing friends experience serious complications—like steroid-induced diabetes—shows just how important that oversight stays.
Pushing for safer corticosteroids has driven research ever since these drugs hit the market. Labs test hundreds of derivatives, aiming for molecules that focus their effects precisely where needed and fizzle out everywhere else. Kids and older adults, who often absorb drugs differently, deserve these improvements the most. Modern science asks tough questions about long-term exposure. Researchers already track changes in bone density, blood markers, and the gut’s fragile balance in people on long steroid regimens. The better medicines manage to protect against flares without turning lives upside-down, the closer healthcare gets to treating the whole person, not just the symptoms.
Steroids like 21-Hydroxypregna-1,4,9(11),16-tetraene-3,20-dione-21-acetate have changed medicine, turning once-devastating diseases into problems people can handle. Every time new versions hit the shelves, health providers weigh their real benefits and risks. Patients can help themselves by staying alert to changes in their own bodies and asking questions before starting new treatments. Open conversations, safer formulations, and smarter monitoring all nudge the field toward fewer side effects and better health for everyone.
Anyone who has ever popped open a new box of medication or skincare wonders about the flip side—the side effects. My first experience reading a long side effect list was both confusing and a little unnerving. It’s not surprising that people get overwhelmed by what they find inside the leaflet. Side effects can range from minor annoyances to, on rare occasions, truly serious issues. There’s a reason the small print looks so dense: countless people want to make the best, safest choice.
Stomach troubles lead the pack with many products. In my own life, taking antibiotics often ends up causing queasiness or a bit of diarrhea. Doctors see it all the time; the gut has a way of reacting to anything new. Skin creams can cause itchiness, redness, or a rash. Even a supplement like vitamin D may surprise you. I remember trying a new brand and ending up with headaches and fatigue, only to later see those exact reactions on an updated label. Nausea, headaches, and mild allergic reactions often show up across different kinds of products, a theme that needs attention from both users and makers.
Most of us worry about the longshot, not just the likely. Severe side effects grab headlines for good reason. Allergic reactions such as swelling or trouble breathing require immediate help. A friend of mine discovered a nut allergy because of a protein powder, despite no warning on the packaging. That scare underlined the gap between real-world risks and what’s officially listed. The FDA and other watchdogs track such cases once products reach wide use, but catching outliers always takes time.
Data shows that genetics, existing health conditions, and even what else you eat or take can shift the side effect picture. For example, people with liver or kidney issues may handle drugs or supplements differently. I saw this with my older relatives; a medication tolerated by most adults gave them joint pain and low energy. Studies back this up: even something as common as OTC painkillers can pose real risks for some. The one-size-fits-all idea never really holds up, and consumers deserve to know that.
Trust begins with straight talk. No one should gloss over what could go wrong, no matter how rare. Companies build confidence by investing in thorough testing and by updating warning labels as new reports roll in. Regular follow-ups and community input catch side effects missed in early trials. Pharmacies and clinics play a role too; the best advice I’ve received came from pharmacists who knew how a new product might interact with my allergies or other meds.
Solving side effect issues means opening lines of communication. Users report reactions, regulators keep tabs, companies make changes. Simple reporting tools, like phone apps, now let anyone flag new problems. Health professionals ought to steer conversations toward possible risks and alternative options, especially for those with complex health profiles. Better transparency and steady feedback drive a safer experience and far greater trust with any new product.
Staring at a name like 21-Hydroxypregna-1,4,9(11),16-Tetraene-3,20-Dione-21-Acetate on a label doesn’t exactly invite confidence. A long winding name can push the average person away, yet real people—patients, doctors, pharmacists—must decide what to do with it. This kind of compound sits squarely in steroid chemistry, often popping up in research tied to corticosteroids or hormone treatments.
Doctors know medicines can never be “one size fits all.” That idea holds true here even more than with everyday drugs. Before handing anyone a dose, pros look at any current meds, hormone levels, and even existing organ function. Drug interactions with compounds like this one can sneak up and turn a promising treatment into trouble.
Some drugs jump right into the bloodstream via injection, others move through skin or travel down the digestive tract. Medical literature often describes acetates similar to this compound as either injectable or oral, although little public data explains the specific best fit for this molecule. Doctors must search through real data and lean on experience with relatives like hydrocortisone or prednisone. In those cases, oral tablets provide steady absorption, but IV or IM injection works for rapid action, especially during crises.
Experience says: Don’t DIY this. Mixing up a solution, measuring tiny amounts, or injecting at home without oversight spells disaster for even seasoned patients. Healthcare teams create protocols because errors have real consequences—underdosing can leave disease unchecked, overdosing causes side effects or organ stress.
Dosing with hormones brings a layered challenge. Too much, and the body fights back with high blood pressure, high sugar, lowered immunity, or even mood swings. Too little, and a person’s symptoms return, or adrenal function drops. The goal stays simple: keep the level steady, mimic the body’s natural rhythm. Doctors learn to titrate—raise or lower doses—based not only on numbers in blood tests but also day-to-day signs like appetite, mood, skin changes, or energy crashes.
No one can ignore how much insurance coverage, local pharmacy stock, or healthcare access shape whether someone sticks with these treatments. High copays, missed doses, or not understanding directions all can erase the benefits in an instant. I’ve watched patients bounce between brand names, compounding pharmacies, and even travel for supplies. A solution often requires not just a prescription, but persistent advocacy from both families and healthcare pros.
Chemical complexity only works if healthcare teams break it down for the person using it. Honest talk, not just printouts filled with jargon, keeps patients safe. Explaining why a drug has to go into the muscle, or needs to be swallowed with food, often marks the difference between a smooth recovery and a return visit.
For rare or research-focused compounds like 21-Hydroxypregna-1,4,9(11),16-Tetraene-3,20-Dione-21-Acetate, clear protocols remain scarce. More robust trials, real-world data, and transparent guidance from reputable medical journals or regulatory bodies could give doctors what they need to tailor dosing. Until then, every use comes down to caution, science, and a little more vigilance than usual.
Asking whether a product needs a prescription usually means facing a wall of confusing rules and half-answers. In my own experience standing in pharmacy lines, I’ve watched people try their best to figure it out, only to leave frustrated. The short answer depends on three things: the product’s ingredients, how it’s marketed, and how it’s used. Simple enough, but rarely clear.
Some products, especially medications, can do real harm if folks use them the wrong way. Take antibiotics as an example. I’ve heard friends insist they just need one round to knock out a cold, though those drugs won’t do a thing for viruses. That kind of misuse drives antibiotic resistance, and resistant bacteria cause longer illnesses and more deaths. The CDC has said about 2.8 million resistant infections happen in the United States each year.
Drugs for blood pressure, diabetes, or mental health also belong behind the counter. Unchecked use might lead to serious complications. Every year, emergency rooms treat thousands of people due to misuse or overdoses of common prescription drugs, according to the FDA.
Supplements and some herbal remedies don’t require a prescription, but that doesn’t make them risk-free. I’ve watched relatives try to fix sleep troubles with over-the-counter melatonin, only to end up groggy and out of sorts. Many supplements interact with regular medications. St. John’s Wort, for example, can affect everything from birth control pills to antidepressants. The FDA has flagged dozens of supplement recalls in recent years due to contamination or hidden prescription drugs.
Governments set the rules for what gets sold where. In the U.S., the FDA checks whether new products are safe and effective. If a product has strong or unpredictable effects, you can only get it with a prescription. Canada and European countries work in similar ways, though sometimes the same item shows up on store shelves here but not there.
Regulating where and how things are sold helps doctors catch risks early. Say you’re buying something for your heart: your doctor can spot drug interactions that could turn dangerous. It’s frustrating for sure, but those checks make real sense once you see the downsides of skipping them.
If you’re not sure about a product’s prescription status, pharmacists can be a real help. They know the details and catch things a quick online search might miss. Websites run by government agencies—like the FDA or Health Canada—keep up-to-date lists of what needs a doctor’s order. I’ve also learned to check the product packaging, since approved meds carry easy-to-spot “Rx Only” labels.
Technology has started to close knowledge gaps. Digital tools like prescription verification apps or online chats with licensed pharmacists offer quick answers. That said, nothing beats face-to-face conversations when safety is at stake. Erring on the side of caution pays off, especially with health decisions.
Drug safety doesn’t just run on theory. I’ve seen friends end up in the ER for pairing medications their doctors never flagged. Mixing meds or combining prescriptions with supplements isn’t rare. It happens everywhere, especially as people age and collect more bottles on the bathroom shelf. One pill alone could fix a problem, but stacking them up without checking interactions can set off trouble nobody expects.
The best example lives close to me. A family member needed blood thinners after heart surgery. Nobody told them about the risk with common pain relievers like ibuprofen. Taking both for a bad back led to a scary bleeding episode. Ibuprofen increases bleeding risks when paired with blood thinners. This isn’t a rare case—it mirrors thousands of emergency visits each year. According to the CDC, adverse drug events send more than a million people to U.S. emergency rooms each year. Older adults make up about half of these admissions because they often juggle many daily medications.
Some combinations spell quick disaster. Blood thinners like warfarin clash with antibiotics such as trimethoprim-sulfamethoxazole. A cholesterol-lowering statin plus some antifungal pills can harm the muscles, even the kidneys. Mixing certain antidepressants with migraine drugs can cause serotonin syndrome, a dangerous reaction that changes mood, blood pressure, and temperature control. Grapefruit juice, sold in every supermarket, changes the way many heart pills work in the body. I learned this lesson myself—my dad’s cholesterol meds worked less when he stuck to his breakfast citrus routine.
Natural therapies do not give anyone a free pass, either. St. John’s Wort, a popular supplement for mild depression, makes birth control less effective and weakens meds for HIV or blood pressure. Some folks skip the doctor to avoid embarrassment or extra costs, but even vitamins or fiber shakes can block med absorption or cause side effects when mixed the wrong way.
Doctors work hard to track everything, but rushed appointments leave gaps. Pharmacists fill some of those holes if folks ask questions or use the same drugstore for all scripts. Unfortunately, many bounce between pharmacies or use an online service and a local spot, leaving no one to see the full list. One solution comes from always sharing an updated medication list at every appointment. It sounds simple but most people rely on memory, which rarely includes doses or ingredient names. Carrying a written or digital list can prevent mistakes.
People often stay quiet about side effects or supplement use because they don’t want to be judged. A culture that encourages honest talk with providers helps everyone. At home, families taking care of parents or grandparents can play a role by keeping track of medicines on a phone or sticky note. Asking "Do these all work together?" could prevent real harm. It’s not about mistrusting doctors. It’s about teams working together, catching mistakes before they happen.
New apps send reminders, warn about bad combinations, or flag recalls. Some insurance plans also call out risky combos. Yet, technology can’t replace asking questions at pick-up or alerting a doctor about all the bottles on the counter. Good habits—reading labels and double-checking—save lives far more often than luck does.
| Names | |
| Preferred IUPAC name | 21-acetoxy-21-hydroxypregna-1,4,9(11),16-tetraene-3,20-dione |
| Other names |
Fluorometholone acetate
Fluorometholone 21-acetate |
| Pronunciation | /ˈhaɪdrɒk.siˌprɛɡ.nə ˌwʌn.fɔrˈnaɪnˌɪˈlɛv.ɪnˌsɪksˈtɛn.tɛrˈiːnˌθri.twɛntiˈdaɪ.oʊn.twɛntiˈwʌn.æs.ɪˌteɪt/ |
| Preferred IUPAC name | 21-acetoxy-21-hydroxypregna-1,4,9(11),16-tetraene-3,20-dione |
| Other names |
Triamcinolone acetate
Acetonide triamcinolone Triamcinolone 21-acetate |
| Pronunciation | /twɛnti wʌn haɪˌdrɒksiˌprɛgna wʌn fɔr naɪn ɪˈlɛvən sɪksˈtiːn tɛˌriːn θri twɛnti daɪˈoʊn twɛnti wʌn æsɪˌteɪt/ |
| Identifiers | |
| CAS Number | 2622-37-3 |
| Beilstein Reference | 626793 |
| ChEBI | CHEBI:76272 |
| ChEMBL | CHEMBL107122 |
| ChemSpider | 22422247 |
| DrugBank | DB01481 |
| ECHA InfoCard | ECHA InfoCard: 100.045.982 |
| EC Number | 1.14.99.10 |
| Gmelin Reference | 1739924 |
| KEGG | C14418 |
| MeSH | D004085 |
| PubChem CID | 137215230 |
| RTECS number | UY9475000 |
| UNII | 7KNP0KII78 |
| UN number | UN1230 |
| CAS Number | 2972-21-6 |
| 3D model (JSmol) | `C1C(=O)CC2=CC(=O)C3C4CCC(=O)C4(C)CC3CC2(C)C1OC(=O)C` |
| Beilstein Reference | 1202057 |
| ChEBI | CHEBI:76234 |
| ChEMBL | CHEMBL3234949 |
| ChemSpider | 21476559 |
| DrugBank | DB00635 |
| ECHA InfoCard | 100.107.216 |
| EC Number | 1.14.99.10 |
| Gmelin Reference | 113715 |
| KEGG | C16516 |
| MeSH | D004715 |
| PubChem CID | 167602 |
| RTECS number | RY2300000 |
| UNII | B1F950168F |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C23H27O5 |
| Molar mass | 414.472 g/mol |
| Appearance | White solid |
| Odor | Odorless |
| Density | 1.27 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 1.82 |
| Vapor pressure | 0.0 Pa (at 25 °C) |
| Acidity (pKa) | 12.68 |
| Basicity (pKb) | 6.22 |
| Refractive index (nD) | 1.583 |
| Viscosity | Viscous oil |
| Dipole moment | 4.6 D |
| Chemical formula | C25H30O5 |
| Molar mass | 412.481 g/mol |
| Appearance | Light yellow crystalline powder |
| Odor | Odorless |
| Density | 1.23 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 2.67 |
| Vapor pressure | 9.69E-11 mmHg at 25°C |
| Acidity (pKa) | 12.59 |
| Basicity (pKb) | 2.94 |
| Refractive index (nD) | 1.610 |
| Dipole moment | 4.40 D |
| Thermochemistry | |
| Std enthalpy of formation (ΔfH⦵298) | -726.4 kJ/mol |
| Std molar entropy (S⦵298) | 433.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -715.3 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -7962 kJ/mol |
| Pharmacology | |
| ATC code | H02AB02 |
| ATC code | H02AB04 |
| Hazards | |
| Main hazards | May cause cancer. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS06,GHS08 |
| Signal word | Warning |
| Hazard statements | H315, H319, H335 |
| Precautionary statements | P261, P264, P271, P272, P273, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P333+P313, P337+P313, P362+P364, P403+P233, P405, P501 |
| Flash point | > 223.3 ± 24.6 °C |
| LD50 (median dose) | LD50 400mg/kg (rat, oral) |
| NIOSH | NMAM 5705 |
| PEL (Permissible) | PEL (Permissible) of 21-Hydroxypregna-1,4,9(11),16-Tetraene-3,20-Dione-21-Acetate is not established. |
| REL (Recommended) | 0.002 mg/m³ |
| IDLH (Immediate danger) | NIOSH has not established an IDLH for 21-Hydroxypregna-1,4,9(11),16-tetraene-3,20-dione-21-acetate. |
| Main hazards | H315, H319, H335 |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS07, GHS08 |
| Signal word | Danger |
| Hazard statements | H315,H319,H335 |
| Precautionary statements | P261, P264, P271, P272, P273, P280, P302+P352, P305+P351+P338, P308+P313, P332+P313, P337+P313, P362+P364, P501 |
| Flash point | >120°C |
| LD50 (median dose) | LD50 (median dose): Mouse intravenous 60mg/kg |
| NIOSH | RG1630000 |
| PEL (Permissible) | Not established |
| REL (Recommended) | 0.01 mg/kg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Hydrocortisone
Prednisolone Prednisone Cortisone acetate Dexamethasone Triamcinolone Betamethasone Methylprednisolone |
| Related compounds |
Cortisone acetate
Prednisolone acetate Hydrocortisone acetate Prednisone acetate Dexamethasone acetate |
Providing high-quality chemical products and logistics solutions for global trade partners.
